Bayer's sevabertinib gets priority review for treatment of non-small cell lung cancer

Return On Information New Jersey

May 31, 2025

Bayer announced that the U.S. Food and Drug Administration (FDA) has accepted the company's new drug application (NDA) and granted priority review designation for the investigation…